Featuring: publicly traded & venture capital companies on the U.S. (NYSE, NASDAQ, AMEX & OTC: BB) and Canadian (TSX & TSX-V) stock exchanges, Investment & Money Management Ideas. |
|
Press Release - Lightlake Therapeutics inc. (LLTP-OTC: BB) |
|
|
As our medication is going to be a opioid antagonist nasal spray patients will simply take the spray just before they feel the need to binge eat, rather than relying on typical dieting methods, or the necessity to take medication lifelong. - Dr. Roger Crystal (Interview published February 11, 2011) |
The Most Powerful Name In Corporate News and Information. |
|
CURRENT ISSUE | COVER ARCHIVES | INDEX | CONTACT | FINANCIALS | MARKETING SERVICES | HOME PAGE |
|
Lightlake
Therapeutics Appoints Professor Martin Wilkins Medical Advisor Lightlake
Therapeutics Inc. ("Lightlake") (OTCBB: LLTP) is pleased to announce
the appointment of Professor Martin Wilkins as Medical Advisor, as
Lightlake continues to build a world-class advisory panel. Martin R. Wilkins is the Professor of Clinical Pharmacology and Head of the Division of Experimental Medicine, Imperial College London and Director of Clinical and Investigative Sciences within Imperial College Healthcare NHS Trust. He is a Consultant Physician within Imperial College Healthcare NHS Trust and has been the Director of the Sir John McMichael Centre for Clinical Research at Hammersmith Hospital since its establishment in 2001. Professor Wilkins is a clinician scientist with a background in clinical pharmacology and toxicology. His primary interest is in proof-of-concept studies in humans.
The Division of Experimental Medicine hosts the Wellcome Trust - GSK Translational Medicine Fellowship Programme at Imperial College. Dr Michael Sinclair,
Chairman of Lightlake Therapeutics commented: 'Professor Wilkins
brings the ability to bridge the gap between academic studies, and
clinical development.' 'He leads a unit with
an international reputation, within a world-class institution, which
will be one of the main centres for our Phase III trial.' About Lightlake Therapeutics Lightlake
Therapeutics is an early stage biopharmaceutical company aiming to
build a solid platform of pharmacological treatments based on our
expertise using opioid antagonists. Significant developments include
the use of an opioid antagonist nasal spray to address binge-eating
obesity. A Phase II trial of this product in Helsinki is due to be
completed during 2011. This press release
contains forward-looking statements. These statements relate to
future events or our future financial performance and involve known
and unknown risks, uncertainties and other factors that may cause
our or our industry's actual results, levels of activity,
performance or achievements to be materially different from any
future results, levels of activity, performance or achievements
expressed, implied or inferred by these forward-looking statements.
In some cases, you can identify forward-looking statements by
terminology such as "may", "will", "should", "could", "would",
"expects", "plans", "intends", "anticipates", "believes",
"estimates", "predicts", "projects", "potential" or "continue" or
the negative of such terms and other comparable terminology. These
statements are only predictions based on our current expectations
and projections about future events. You should not place undue
reliance on these statements. Actual events or results may differ
materially. In evaluating these statements, you should specifically
consider various factors. These and other factors may cause our
actual results to differ materially from any forward-looking
statement. We undertake no obligation to update any of the
forward-looking statements after the date of this presentation to
conform those statements to reflect the occurrence of unanticipated
events, except as required by applicable law. Contacts: Lightlake Therapeautics Inc. Dr Roger Crystal CEO roger.crystal@lightlake.fi Lightlake Therapeautics Inc. Dr Michael Sinclair Chairman michael.sinclair@lightlake.fi www.lightlake.org Press Inquiries: TypeA Consulting, Inc. Christine Barisheff Christine@typeaconsult.com SOURCE: Lightlake Therapeutics Inc. mailto:roger.crystal@lightlake.fi mailto:michael.sinclair@lightlake.fi http://www.lightlake.org mailto:Christine@typeaconsult.com Copyright 2011 Marketwire, Inc., All rights reserved
|
ceocfointerviews.com does not purchase or
make
recommendation on stocks based on the interviews published.